The Peptide Research HubPeptidesUK4U

Comparison

Retatrutide vs Tirzepatide

The next-generation triple agonist vs the current dual-agonist leader. Retatrutide adds glucagon receptor activity on top of GLP-1/GIP — here is what that changes in the data and in the lab.

Retatrutide

Triple GLP-1 / GIP / Glucagon agonist. Highest weight-loss signal in trials to date.

Mechanism
GLP-1 + GIP + Glucagon
Half-life
~6 days
Dosing cadence
Weekly
Phase 2 weight loss
~24% at 48 weeks
Status
Investigational

Strengths

  • · Highest peak weight-loss reported in any GLP-1-class trial
  • · Glucagon arm increases resting energy expenditure
  • · Weekly cadence, familiar handling

Trade-offs

  • · Not yet approved — Phase 3 ongoing
  • · GI side effects meaningful at higher doses
  • · Long-term safety data still limited
Full Retatrutide guide Research-grade Retatrutide at PeptidesUK4U

Tirzepatide

Dual GLP-1 / GIP agonist. Approved, established, still class-leading in clinic.

Mechanism
GLP-1 + GIP
Half-life
~5 days
Dosing cadence
Weekly
SURMOUNT weight loss
~21% at 72 weeks
Status
Approved (Mounjaro / Zepbound)

Strengths

  • · Full Phase 3 evidence base
  • · Approved indications for T2D and obesity
  • · Well-characterised handling and titration

Trade-offs

  • · Lower peak weight loss than retatrutide in cross-trial reads
  • · No glucagon arm — energy expenditure less pronounced
Full Tirzepatide guide Research-grade Tirzepatide at PeptidesUK4U

Which one wins?

On paper retatrutide is the more potent molecule — Phase 2 data suggests roughly 3 percentage points more weight loss than the best tirzepatide numbers. But retatrutide is still investigational; tirzepatide has years of real-world use and full outcome data behind it.

For research handling both behave the same: lyophilised powder, reconstitute with BAC water, refrigerate once mixed. What actually determines your outcome is the purity of the vial you receive — a 92% pure retatrutide will underperform a 99% pure tirzepatide every single time.

Mechanism: dual vs triple agonism

Tirzepatide activates two receptors (GLP-1, GIP). Retatrutide adds a third — the glucagon receptor — which increases hepatic energy expenditure and lipolysis. The three-way balance is what unlocks the higher weight-loss ceiling.

See our GLP-1 brand names map for how each molecule maps to its clinical name, and the compound background at PeptidesUK4U.

Dosing and titration

Both are weekly subcutaneous with slow 16–20 week titration to blunt GI effects. Use a reconstitution calculator to convert vial mg + BAC water mL into exact U-100 units.

Storage and handling

Lyophilised powder stable months at 2–8 °C. Reconstituted vials ~28 days refrigerated — see the storage & stability guide. Source only from suppliers who publish batch-specific HPLC CoAs.

Editorial partner

Referenced supplier: PeptidesUK4U

Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.

  • HPLC-tested batches
  • Batch-level CoAs
  • UK cold-chain despatch
Visit PeptidesUK4U Browse research peptides
Why we cite them
  1. 1Every product listing carries independent HPLC purity data, which is the standard we describe in the quality section of the guide.
  2. 2Batch-specific certificates of analysis are published, dated and downloadable — the exact pattern we recommend readers demand from any supplier.
  3. 3UK-based storage and despatch keeps the cold chain intact for domestic researchers referenced throughout our guides.

Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.